
NEWS
COVID-19 - Impact on Financial Sector - 30 April 2020

Related Lawyer(s)
Please find below a summary of COVID-19 developments relevant to our clients; these alerts are dedicated to following up on the financial regulators’ responses to the crisis. We have also created a COVID-19 Resource Center to offer legal and business insights as this crisis continues to evolve. We wish you and your loved ones well.
If you have any questions please feel free to contact:
Tom Van Dyck |
Freya Mareels |
Wim Dedecker |
30/04/2020 |
The FSMA publishes a Q&A about the impact of COVID-19 on the obligations of listed companies |
The Q&A is intended:
|
30/04/2020 | Febelfin – Data about (digital) payments in the coronavirus and the guarantee scheme |
During the coronavirus, and combined with the increased limit for contactless payments, the use of non-contact payments has doubled compared to last year. In light of the guarantee scheme, banks have to date granted corporate loans more than 115,000 times deferred. In total, this concerns an underlying credit volume of 17 billion euros or an average of 145,000 per credit with companies. In the meantime, the guarantee scheme has also been activated for all new loans and credit lines with a maximum term of 12 months. The first figures show that in April, banks extended more than 17,000 new loans to companies (with and without a state guarantee) amounting to just over 4 billion euros. |
29/04/2020 | EIB and CEPI sign advisory agreement to accelerate the development of vaccines against infectious diseases |
The European Investment Bank (EIB) and the Coalition for Epidemic Preparedness Innovations (CEPI) have signed a landmark advisory agreement to collaborate on the development of innovative financing schemes to support vaccines development across the globe. Under this partnership delivered through the InnovFin Advisory programme, the EIB will provide strategic financial advice and support to CEPI and its members (private and public companies and research institutes) on potential financing solutions from the EIB Group and/or external financing options. The goal is to deploy large-scale vaccine development projects, making such solutions more readily available around the world. |
30/04/2020 |
As a result of the COVID-19 outbreak, EIOPA will carry out extraordinary calculations on a weekly basis to monitor the evolution of the relevant risk-free interest rate term structures (RFR) and the symmetric adjustment to equity risk (EDA). The information will be published on a specific area of the website created for this purpose both for RFR and EDA named “Extraordinary weekly updates”. |
Copyright - Please do not quote without permission. Please note that this alert is not a legal advice.